Home Tags ALCANZA trial

Tag: ALCANZA trial

Positive Phase III ECHELON-1 Trial Data Leads to FDA Breakthrough Therapy...

U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with chemotherapy for the frontline...

U.S. FDA Grants Priority Review for Brentuximab Vedotin in Cutaneous T-Cell...

The United States Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the Phase...

Breakthrough Therapy Designation for Brentuximab Vedotin in CD30-expressing Mycosis Fungoides and...

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for brentuximab vedotin (Adcetris®; Seattle Genetics) for the treatment of patients with...

Alcanza Trial Demonstrates Highly Statistically Significant Improvement in Rate of Objective...

Results of the phase III Alcanza trial evaluating brentuximab vedotin (Adcetris®; Takeda Pharmaceutical and Seattle Genetics)  in patients with cutaneous T-cell lymphoma (CTCL) shows...

European Commission Approves Brentuximab Vedotin for Consolidation Treatment in Post-Transplant Hodgkin...

The European Commission (EC) has extended the current conditional marketing authorization of brentuximab vedotin (Adcetris®/Seattle Genetics/Takeda Oncology) and approved the drug for the treatment of...

Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...

Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy.  Oral...

X